You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
Veralox Therapeutics Submits IND to US FDA for Phase I Trial of VLX-1005 to Treat Heparin-Inducted Thrombocytopenia
Login
Username:

Password:


Related Headlines

Curasight reports encouraging preliminary Phase 1 data for uTREAT in glioblastoma

Sanofi secures EU approval for subcutaneous Sarclisa with on-body injector

Sciwind Biosciences reports positive study data on ecnoglutide versus semaglutide

OriCell's GPC3 CAR-T Phase II hepatocellular carcinoma trial receives Chinese regulatory clearance

Bayer reports positive Phase III FIND-CKD results for Kerendia in non-diabetic chronic kidney disease

Owkin to build AI agents as part of K Pro collaboration with Sanofi

Gilead and Lakefront complete Ouro Medicines acquisition to expand autoimmune disease pipeline

Kexing Biopharm begins enrolment for Phase I trial of GB10 in China

Lupeng Pharmaceutical's rocbrutinib receives Chinese approval to treat R/R mantle cell lymphoma

Pharming secures FDA acceptance of Joenja filing for children with APDS

UCB and Biogen present Phase 3 data highlighting potential of dapirolizumab pegol in lupus treatment

Persist AI partners with Microsize and Micromacinazione to launch drug formulation platform

RedHill Biopharma advancing opaganib options for Ebola outbreak

Sun Pharma receives American Skin Association 2026 Corporate Leadership Award

ADC Therapeutics reports trial results for ZYNLONTA - rituximab combination in relapsed or refractory diffuse large B-Cell lymphoma

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2026